The study is testing a new medicine (NNC0487-0111) for weight control in Chinese people with BMI between 24 kilogram per meter square (kg/m2) and 34.9 kg/m2. The aim of the study is to see how safe the study medicine is and how it behaves in human body. Participants will either get the study medicine or placebo (a "dummy medicine" similar to the study medicine but without active ingredients) and which treatment they get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors but has previously been tested in humans. This study will last for up to 53 days.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
36
Participants will receive single dose (level 1, level 2, level 3) injection of NNC0487-0111 A subcutaneoulsy.
Participants will receive single dose (level 1, level 2, level 3) injection of placebo A subcutaneoulsy.
Jinan Central Hospital
Jinan, Shandong, China
Number of treatment emergent adverse events (TEAEs)
Number of events
Time frame: From NNC0487-0111 administration (Day 1) to completion of the end of study visit (Day 23)
AUC0-∞,SD; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose
h\*nmol/L
Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 23)
Cmax,SD; the maximum plasma concentration of NNC0487-0111 after a single dose
nmol/L
Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 23)
tmax,SD; the time of maximum plasma concentration of NNC0487-0111 after a single dose
h
Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 23)
t1/2,SD; the terminal half-life of NNC0487-0111 after a single dose
h
Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 23)
Relative change in body weight
Time frame: From baseline Day 1 until completion of the end of study visit (Day 23)
Change in fasting plasma glucose
mmol/L
Time frame: From baseline Day 1 until completion of the end of study visit (Day 23)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.